Sensitivity to Intravenous Nicotine: Genetic Moderators
Overview
- Phase
- Phase 1
- Intervention
- Nicotine
- Conditions
- Nicotine Dependence
- Sponsor
- Yale University
- Enrollment
- 213
- Locations
- 1
- Primary Endpoint
- primary hypotheses will test the influence of OPRM1 A118G status on subjective responses to IV nicotine, which will be measured with the drug effects questionnaire (DEQ).
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV nicotine when compared to those with AA genotype.
Detailed Description
Increasing evidence suggest that MOR contribute to nicotine's rewarding effect. Further, the functional OPRM1 A118G variant has been linked to rewarding effects of alcohol in alcohol users and to nicotine in female smokers. Since no previous studies examined the influence of the A118G variation on pure nicotine responses, the next logical step is to evaluate how this genetic polymorphism affects nicotine's rewarding, cognitive, and physiological effects using IV nicotine administration in male and female smokers. In addition, the association of the G398A polymorphism of the CHRNA5 gene (rs16969968) with maximal response to nicotinic agonists justifies examination of this SNP as a moderator of IV nicotine sensitivity in humans (Bierut et al. 2008). This SNP will be examined in an exploratory fashion since it is not feasible to fully stratify the study sample for multiple SNPs. The frequency of rs16969968 SNP ranges from 35%-42% among those of European ancestry, making it feasible to examine this variation in our subject sample. Currently this study is active and enrollment is continuing. Currently there are 205 completers and on going.(June 2014)
Investigators
Mehmet Sofuoglu
Principle Investigator
Yale University
Eligibility Criteria
Inclusion Criteria
- •Female and male smokers, aged 18 to 50 years;
- •History of smoking daily for the past 12 months, 10-25 cigarettes daily;
- •Not seeking treatment at the time of the study for nicotine dependence;
- •Have a FTND score of at least 5 and CO level \> 10ppm;
- •In good health as verified by medical history, screening examination, and screening laboratory tests;
- •For women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods.
Exclusion Criteria
- •History of major medical illnesses that the physician investigator deems as contraindicated for the patient to be in the study;
- •Regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent psychiatric diagnosis and treatment for Axis I disorders including major depression, bipolar affective disorder, schizophrenia or panic disorder;
- •Abuse of alcohol or any other recreational or prescription drugs.
Arms & Interventions
Nicotine
Intravenous Nicotine
Intervention: Nicotine
Saline
Saline infusion
Intervention: saline
Outcomes
Primary Outcomes
primary hypotheses will test the influence of OPRM1 A118G status on subjective responses to IV nicotine, which will be measured with the drug effects questionnaire (DEQ).
Time Frame: Injections 30 minutes apart